IMMUNOBLUE, LLC

Biotech · Private

Personalized autologous T cell therapy (IB-T cells) generated using Prussian blue nanoparticle photothermal therapy to activate immunogenic tumor cell death for glioblastoma treatment

Grants
$1.7M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · An Engineered Nanoimmunotherapy for Melanoma$200,001
Federal grantDepartment of Health and Human Services · Phase I · Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles$399,669
Federal grantDepartment of Health and Human Services · Phase II · Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles$1,135,290
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2997Pathways Bioscience, LLC——
2998End2End Genomics LLC——
2999Tolerance Bio Inc.—$15M
3000IMMUNOBLUE, LLC——
3001SOUVIE BIODELIVERY LLC——
3002Riboscience LLC——
3003AAIIT LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.